Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | CFD | P00746 | 2/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | TOP1 | P11387 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12957304 | 0.94 | METTL3 (0.69) | METTL3MAPTKDM4EPOLBLMNA | |
| SCHEMBL11948614 | 0.91 | METTL3 (0.58) | METTL3MAPTKDM4EPOLBLMNA | |
| SCHEMBL16850607 | 0.91 | METTL3 (0.58) | METTL3MAPTKDM4EPOLBLMNA | |
| SCHEMBL13861862 | 0.90 | METTL3 (0.69) | METTL3MAPTKDM4EPOLBLMNA | |
| SCHEMBL30697922 | 0.88 | METTL3 (0.81) | METTL3MAPTKDM4EPOLBLMNA | |
| SCHEMBL1050772 | 0.88 | METTL3 (0.81) | METTL3MAPTKDM4EPOLBLMNA | |
| SCHEMBL2280900 | 0.88 | METTL3 (0.81) | METTL3MAPTKDM4EPOLBLMNA | |
| SCHEMBL13225647 | 0.88 | METTL3 (0.81) | METTL3MAPTKDM4EPOLBLMNA | |
| SCHEMBL22930491 | 0.85 | METTL3 (0.86) | METTL3MAPTPOLBGAATP53 | |
| SCHEMBL13861860 | 0.84 | METTL3 (0.72) | METTL3MAPTCFDGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197847-B1 | DEUTERATED 4 -OXOQUINOLINE DERIVATIVE FOR THE TREATMENT OF HIV INFECTION | CONCERT PHARMACEUTICALS INC (US) | 2012-11-07 | — | — | EP | disclosed |
| US-7994194-B2 | 4-oxoquinoline derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20090143427-A1 | 4-Oxoquinoline derivatives | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143427-A1 | 4-Oxoquinoline derivatives | CYP3A4, PIK3CA, CYP3A5 | METTL3 2275/4885MAPT 2253/4885KDM4E 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.